Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Lifts Profit Outlook as Sales Rise
08:42am, Friday, 31'st Oct 2025
AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.
AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.
08:20am, Friday, 31'st Oct 2025
Revenue attributed to AbbVie's oncology and aesthetics portfolio declined in the quarter.
AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs
07:54am, Friday, 31'st Oct 2025
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.
AbbVie Reports Third-Quarter 2025 Financial Results
07:49am, Friday, 31'st Oct 2025
Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
05:00pm, Wednesday, 29'th Oct 2025
Allergan Aesthetics gives patients exciting BOTOX® Cosmetic offers only in the Allē app Buy one $50 gift card, get one free, plus, register, book a consultation, and get treated for a chance to win
In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facia
AbbVie: Deep Discount Before Earnings
11:28am, Tuesday, 28'th Oct 2025
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
10:40am, Tuesday, 28'th Oct 2025
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
09:50am, Tuesday, 28'th Oct 2025
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?
06:26am, Tuesday, 28'th Oct 2025
Englander more than quintupled his hedge fund's position in AbbVie in Q2. AbbVie offers an impressive dividend record and a solid dividend yield.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade
11:21am, Sunday, 26'th Oct 2025
AbbVie put a major patent cliff behind it, and won't face another one anytime soon. Apple is building up its services business while looking for ways to get around the threat of tariffs.
Wall Street Week Ahead
07:01am, Sunday, 26'th Oct 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Pharmaceutical Stocks To Watch Now – October 24th
02:40am, Sunday, 26'th Oct 2025
Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks a
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
11:01am, Friday, 24'th Oct 2025
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
